The Breast : official journal of the European Society of Mastology

01 17 October 2026

DOI 10.1016/j.breast.2026.104946

Current state and future potential of radiopharmaceutical therapy in breast cancer

Open DOI

Joyce O’SHaughnessy, Neil K. Taunk, Gary A. Ulaner

02 13 October 2026

DOI 10.1016/j.breast.2026.104943

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

Open DOI

Thomas Grinda, Matthieu Carton, Stefania Morganti et al.

03 12 October 2026

DOI 10.1016/j.breast.2026.104935

To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission

Open DOI

Han Yi Lee, Whee Sze Ong, Vivianne Tjan-Heijnen et al.

04 7 October 2026

DOI 10.1016/j.breast.2026.104944

Belgian validation of the INFLUENCE 3.0 model predicting 5-year locoregional and contralateral breast cancer recurrence

Open DOI

Aline van der Vorst, Carlijn Grimberg, Marissa C. van Maaren et al.

05 1 October 2026

DOI 10.1016/j.breast.2026.104940

Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare system

Open DOI

André Mattar, Francisco Pimentel Cavalcante, Nelson Francisco Correa-Netto et al.

06 29 September 2026

DOI 10.1016/j.breast.2026.104942

Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial

Open DOI

Carmine De Angelis, Alessandra Rosa, Virginia Delucchi et al.

07 29 September 2026

DOI 10.1016/j.breast.2026.104941

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

Open DOI

Alexis LeVee, Saya Jacob, Samantha Fisch et al.

08 29 September 2026

DOI 10.1016/j.breast.2026.104939

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France

Open DOI

JeanSebastien Frenel, Alexandre de Nonnevile, Catherine Guerin-Charbonnel et al.

09 27 September 2026

DOI 10.1016/j.breast.2026.104933

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

Open DOI

William Jacot, Pauline Macouillard, Suyuan Zhang et al.

10 26 September 2026

DOI 10.1016/j.breast.2026.104938

Subtype-specific screen-detected and interval breast cancer rates in population screening: a BreastScreen Queensland cohort study

Open DOI

Naomi Noguchi, Nick Ormiston-Smith, Michael Luke Marinovich et al.